Abiopharma

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001918704-26-011864 <b>Size:</b> 633 KB

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001918704-26-011863 <b>Size:</b> 639 KB

New Form 424B2 - TORONTO DOMINION BANK <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001140361-26-018741 <b>Size:</b> 1 MB

(30% Negative) SUPERIOR GROUP OF COMPANIES, INC. (SGC) Reports Q2 2026 Financial Results

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001918704-26-011862 <b>Size:</b> 989 KB

MAKO MINING CORP. (MAKO) Files Form 6-K

Intention to conduct a tender for classified investors regarding the issuance of BONDS 2 on 5.5.26

(30% Negative) AXSOME THERAPEUTICS, INC. (AXSM) Reports Q2 2026 Financial Results

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001918704-26-011861 <b>Size:</b> 928 KB

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Interest / Changes in Interest - Tammie Tham

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Interest / Changes in Interest - Mark Duncan

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Interest / Changes in Interest - Lim Wee Kian

(90% Positive) KRYSTAL BIOTECH, INC. (KRYS) Announces Enrollment Update for revenue Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Interest / Changes in Interest - David Toh

(19% Negative) BIOCRYST PHARMACEUTICALS INC (BCRX) Announces Delay in angioedema Trials for hereditary angioedema (HAE) in Europe Due to Regulatory Process